In vitro Evaluation of Antibacterial Efficacy using Passiflora foetida Activated Carbon

Activated carbon (AC) has found its attention in pollution control and wastewater treatment to remove various pollutants. Activated carbon can be prepared by physical and chemical activation methods. The chemical activation methods were advantageous over physical activation due to process accomplishment at lower temperature and greater yield which avoids burn-off char. Activated carbon was usually used as an adsorbent for dye removal from wastewater which could be related to their extended surface area, high adsorption capacity, microporous structure and special surface reactivity. Microbial pollution and contamination have produced various problems in industrial and medical fields. Based on this, the present study was attempted on the preparation of activated carbon from Passiflora foetida and evaluating for its antibacterial efficacy against twelve different microorganisms by agar well diffusion method. The results were found to be very effective with higher zone of inhibition against almost all the microorganisms tested. Moreover, the activity was considerably more against Shigella flexneri (MTCC 1457) and Klebsiella pneumoniae (MTCC 10309).In addition to this, the shake flask test in saline had proved that the colonial growth of E.coli was inhibited with respect to the concentration of activated carbon and time of incubation.Â

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study

© 2022 The Authors. Published by Taylor & Francis. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1080/16078454.2022.2082725Objectives There are no real-world data describing infection morbidity in relapsed/refractory myeloma (RRMM) patients treated with anti-CD38 isatuximab in combination with pomalidomide and dexamethasone (IsaPomDex). In this UK-wide retrospective study, we set out to evaluate infections experienced by routine care patients who received this novel therapy across 24 cancer centres during the COVID-19 pandemic. Methods The primary endpoint was infection morbidity (incidence, grading, hospitalization) as well as infection-related deaths. Secondary outcomes were clinical predictors of increased incidence of any grade (G2–5) and high grade (≥G3) infections. Results In a total cohort of 107 patients who received a median (IQR) of 4 cycles (2–8), 23.4% of patients experienced ≥1 any grade (G2–5) infections (total of 31 episodes) and 18.7% of patients experienced ≥1 high grade (≥G3) infections (total of 22 episodes). Median time (IQR) from start of therapy to first episode was 29 days (16–75). Six patients experienced COVID-19 infection, of whom 5 were not vaccinated and 1 was fully vaccinated. The cumulative duration of infection-related hospitalizations was 159 days. The multivariate (MVA) Poisson Regression analysis demonstrated that a higher co-morbidity burden with Charlson Co-morbidity Index (CCI) score ≥4 (incidence rate ratio (IRR) = 3, p = 0.012) and sub-optimal myeloma response less than a partial response (<PR) (p = 0.048) are independent predictors of ≥ G3 infections. Conclusion Our study described initial results of infection burden during IsaPomDex treatment. We recommend close monitoring particularly in elderly patients with co-morbidities, the effective use of an-infective prophylaxis, as well as optimal vaccination strategies, to limit infections

Increasing frailty is associated with higher prevalence and reduced recognition of delirium in older hospitalised inpatients: results of a multi-centre study

Purpose: Delirium is a neuropsychiatric disorder delineated by an acute change in cognition, attention, and consciousness. It is common, particularly in older adults, but poorly recognised. Frailty is the accumulation of deficits conferring an increased risk of adverse outcomes. We set out to determine how severity of frailty, as measured using the CFS, affected delirium rates, and recognition in hospitalised older people in the United Kingdom. Methods: Adults over 65 years were included in an observational multi-centre audit across UK hospitals, two prospective rounds, and one retrospective note review. Clinical Frailty Scale (CFS), delirium status, and 30-day outcomes were recorded. Results: The overall prevalence of delirium was 16.3% (483). Patients with delirium were more frail than patients without delirium (median CFS 6 vs 4). The risk of delirium was greater with increasing frailty [OR 2.9 (1.8–4.6) in CFS 4 vs 1–3; OR 12.4 (6.2–24.5) in CFS 8 vs 1–3]. Higher CFS was associated with reduced recognition of delirium (OR of 0.7 (0.3–1.9) in CFS 4 compared to 0.2 (0.1–0.7) in CFS 8). These risks were both independent of age and dementia. Conclusion: We have demonstrated an incremental increase in risk of delirium with increasing frailty. This has important clinical implications, suggesting that frailty may provide a more nuanced measure of vulnerability to delirium and poor outcomes. However, the most frail patients are least likely to have their delirium diagnosed and there is a significant lack of research into the underlying pathophysiology of both of these common geriatric syndromes

IN VITRO CYTOTOXIC AND APOPTOTIC EFFECT OF PASSIFLORA FOETIDA AGAINST CERVICAL CANCER CELLS AND ITS FOURIER TRANSFORM INFRARED PROFILING

  Objective: This study was aimed on the analysis of cytotoxic and apoptotic action of Passiflora foetida followed by identification of the functional groups responsible for the activity.Methods: In this study, cytotoxic and apoptotic effect of methanol extract of P. foetida were analyzed by treating HeLa cell line cultures with different concentrations of the extract (25, 50, 75, 100, and 125 μg/ml), and thereby the activity was ratified by 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay and propidium iodide staining. The functional groups of the bioactive compounds for the effectiveness of the treatment were known by Fourier transform infrared spectroscopy analysis (FTIR).Results: The cytotoxic activity was found to be increased in a dose-dependent manner with inhibitory concentration value of 21.55 μg/ml and showed an effective apoptosis. Further, FTIR analysis confirmed the presence of functional groups of alkaloids, flavonoids, saponins, steroids, terpenoids, phenols and cardiac glycosides which might be responsible for the aforesaid activity.Conclusion: The cytotoxic and apoptotic action of P. foetida was proved to be very effective, and the tenable functional groups were identified

Not Available

Not AvailableNot AvailableNot Availabl

Efficacy of isatuximab with pomalidomide and dexamethasone in relapsed myeloma: Results of a UK-wide real-world dataset

This is an accepted manuscript of a paper due to be published by Lippincott, Williams & Wilkins in HemaSphere (in press). The accepted manuscript of the publication may differ from the final published versionReal-world data on the efficacy and tolerability of isatuximab with pomalidomide and dexamethasone (IsaPomDex) in relapsed/refractory myeloma (RRMM) patients have not been reported. In this UK-wide retrospective study, IsaPomDex outcomes were evaluated across 24 routine care cancer centres. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), duration of response (DOR) for patients who achieved an objective response (≥PR), and adverse events (AEs). In a total cohort 107 patients, median follow up (IQR) was 12.1 months (10.1-18.6 months), median age (IQR) was 69 years (61-77). Median (IQR) Charlson Co-morbidity index (CCI) score was 3 (2- 4); 43% had e-GFR<60 ml/min. Median (IQR) number of prior therapies was 3 (3-3). Median (IQR) number of IsaPomDex cycles administered was 7 (3-13). ORR was 66.4%, with responses categorised as ≥VGPR: 31.8%, PR: 34.6%, SD: 15.9%, PD: 15% and unknown 2.8%. Median PFS was 10.9 months. Median DOR was 10.3 months There was no statistical difference in median PFS by age (<65: 10.2 vs. 65-74 13.2 vs. ≥75: 8.5 months, log-rank p=0.4157), by CCI score (<4: 10.2 months vs. ≥4: 13.2, log-rank p=0.6531), but inferior PFS was observed with renal impairment (≥60: 13.2 vs. <60: 7.9 months, log-rank p=0.0408). Median OS was 18.8 months. After a median of 4 cycles, any grade AEs were experienced by 87.9% of patients. The most common ≥G3 AEs were neutropenia (45.8%), infections (18.7%) and thrombocytopenia (14%). Our UK-wide IsaPomDex study demonstrated encouraging efficacy outcomes in the real-world, comparable to ICARIA-MM trial

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients

This is an accepted manuscript of an article published by Wiley on 31/01/2023, available online: https://doi.org/10.1111/bjh.18672 The accepted version of the publication may differ from the final published version.Published versio